Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GmPcides are a class of small molecule antibacterial agents developed by Quretech Bio, based on a ring-fused 2-pyridone scaffold. These compounds are specifically designed to combat infections caused by Gram-positive bacteria, including multidrug-resistant pathogens such as Methicillin-resistant *Staphylococcus aureus* (MRSA) and Vancomycin-resistant *Enterococcus* (VRE). GmPcides function by disrupting the bacterial cell membrane or interfering with cell wall synthesis, and they are being investigated both as standalone bactericidal agents and as potentiators to restore the efficacy of conventional antibiotics against resistant strains. The program is currently in the preclinical stage for several indications, including acute bacterial skin and skin structure infections (ABSSSI) and *Clostridioides difficile* infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GmPcides.